

## Patients' and consumers' organisation funding sources

**NAME OF ORGANISATION:** European Society of Oncology Pharmacy (ESOP)

**YEAR:** 2025

Industry <sup>1</sup> related income <sup>2</sup>		
Name of company/ funder	Amount of income	% of overall organisation's income
B. Braun	1.500,00 €	2,75 %
Non-industry related income		
Source of funding <sup>3</sup>	Amount of income	% of overall organisation's income
Participation fees EUSOP - e-Learning	4.165,00 €	7,62 %
Participation fees ExCOP	24.350,00 €	44,58 %
Participation EUSOP National Events	1.065,00 €	1,95 %
Membership fees	18.450,00	33,78 %

<sup>1</sup> Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

<sup>2</sup> This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.


<sup>3</sup> E.g. membership fees, donations.

EU supported project: Protect-Europe 230303	183,07 €	0,34 %
EU supported project: Smartcare	4.194,40 €	7,68 %
EU supported project: INTERACT 100	5.392,80 €	8,68 %
Bank interests	454,53 €	0,83 %
VAT	261,23 €	0,48 %
<b>Subtotal:</b>	53.123,23 €	97,25 %
<b>TOTAL<sup>4</sup>:</b>	54.623,23 €	100 %

Information required to be included on organisation's website	Please include links below:
<ul style="list-style-type: none"> <li>Overall proportion of industry and non-industry: <b>Industry 2,75 % Non-Industry 97,25 %</b></li> </ul>	
<ul style="list-style-type: none"> <li>Percentage of the highest contribution from a single company: <b>2,75 %</b></li> </ul>	

### Comments/explanatory notes:

<sup>4</sup> In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).



When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2015/05/WC500187018.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf)